Long COVID treated successfully with antivirals in a rituximab-treated follicular lymphoma patient with persistent negative-antibodies to SARS-CoV2

Long COVID treated successfully with antivirals in a rituximab-treated follicular lymphoma patient with persistent negative-antibodies to SARS-CoV2

Highlights

• Persistence of SARS-CoV-2 infection among immunocompromised patients are due to inability of the immune system to eliminate the virus.
• Treatment with anti-CD20 monoclonal antibodies (as in lymphoma patients) causes lack in antibody response to both the COVID-19 vaccine and acute COVID-19 infection.
• Aggressive treatment with antivirals and long-acting monoclonal antibodies against SARS-CoV-2 may be lifesaving among these vulnerable immunocompromised patients.

Abstract
Long COVID is a well-known complication to COVID-19 that affect millions of people worldwide and causes wide range of symptoms.
We present a rare case of a previously diagnosed follicular lymphoma patient, who had a long COVID with persistent negative SARS-CoV-2 antibodies and required an aggressive antiviral treatment.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284434/